staging and risk assessment
In addition to a complete history and physical examination, staging procedures should include the following: chest X-ray, complete blood count, liver and renal function tests, lactate dehydrogenase and sodium levels, and a computed tomography (CT) scan of chest and upper abdomen.
In patients with symptoms or abnormal physical examination suggesting metastasis, additional tests are bone scintigraphy, CT scan or magnetic resonance imaging of the brain, and bone marrow biopsy. Once any one of these tests is positive detecting metastases, there is no need to proceed with the rest of the tests [V, D] .
Patients are usually staged as limited disease or extensive disease according to a simple two-stage system developed by the Veteran's Administration Lung Cancer Study Group.
limited disease
The definition is on the basis of the possibility of encompassing all detectable tumor within a 'tolerable' radiotherapy port. Patients with limited disease have tumor deposits restricted to one hemithorax with regional lymph node metastasis including ipsilateral hilar, ipsilateral supraclavicular, mediastinal, and contralateral hilar nodes.
extensive disease
Any tumor beyond the bounds defined above including ipsilateral lung metastases and malignant pleural effusion.
treatment of limited disease
Standard regimens in limited disease, as well as for patients diagnosed at surgery, include a variety of platinum-containing regimens [I, A].
Limited disease patients should be treated with four to six cycles of etoposide-cisplatin with thoracic radiotherapy [II, A].
Thoracic radiotherapy increases local control and survival in limited disease patients. Several studies suggest starting concurrent thoracic radiotherapy early during chemotherapy [II-III, A].
Prophylactic cranial irradiation is indicated in patients with complete remission from limited disease since it reduces the lifetime risk of cerebral metastases and improves survival [II, B].
Multiple trials have shown that maintenance chemotherapy is not effective in improving survival and four to six cycles of chemotherapy is considered optimal [II, A].
treatment of extensive disease
Chemotherapy with the same regimens as for limited disease and given for four to six cycles is the treatment of choice. In Europe, doxorubicin combinations were until recently commonly given in extensive disease patients, but etoposide-platinum regimens are now increasingly used in this group of patients [II, A]. 
second-line chemotherapy

follow-up
There is no evidence that follow-up of asymptomatic patients is needed. Specific examinations should be as clinically indicated.
For patients who survive long-term, monitoring for development of a second primary may be considered. 
